Feasibility Study of Omega-3 Fatty Acids in Dialysis Patients
| Status: | Completed |
|---|---|
| Conditions: | Peripheral Vascular Disease |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 4/2/2016 |
| Start Date: | October 2009 |
| End Date: | December 2010 |
| Contact: | Heather A Muster, MD, MS |
| Email: | Heather-muster@uiowa.edu |
| Phone: | 319-384-8197 |
Feasibility of Omega-3 Fatty Acid Supplementation in Adult Hemodialysis Patients
Cardiovascular disease and mortality is the largest comorbidity within the dialysis
population. Nearly 50% of hemodialysis patients will have congestive heart failure at
initiation. According to the most recent United States Renal Data System (USRDS), 40% of
incident dialysis patients will have a cardiovascular event or die within the first 9 months
of dialysis. It has been postulated that Omega-3 fatty acids could provide beneficial
cardioprotection in hemodialysis patients. The investigators propose to evaluate Omega-3
fatty acid doses on cardiovascular parameters in an incident hemodialysis population.
Initially, this will be a pilot study. Ultimately, the information will be used to
adequately plan for a larger intervention trial using Omega-3 fatty acids in incident
hemodialysis patients.
population. Nearly 50% of hemodialysis patients will have congestive heart failure at
initiation. According to the most recent United States Renal Data System (USRDS), 40% of
incident dialysis patients will have a cardiovascular event or die within the first 9 months
of dialysis. It has been postulated that Omega-3 fatty acids could provide beneficial
cardioprotection in hemodialysis patients. The investigators propose to evaluate Omega-3
fatty acid doses on cardiovascular parameters in an incident hemodialysis population.
Initially, this will be a pilot study. Ultimately, the information will be used to
adequately plan for a larger intervention trial using Omega-3 fatty acids in incident
hemodialysis patients.
Inclusion Criteria:
- Age > 18 years old
- Initiated dialysis in past 3 months
- Signed informed consent
- Attending University of Iowa dialysis unit for duration of the study
Exclusion Criteria:
- Age >70
- Unable to provide consent
- Currently taking fish oil supplementation
- rhythm other than sinus
- implantable cardioverter-defibrillator
- pacemaker
- myocardial infarction,revascularization or unstable angina in past 3 months
- other hospitalization in past 3 months
- symptomatic heart failure
- known left ventricular ejection fraction < 30%
- history of a significant bleeding disorder
- severe bleeding episode requiring hospitalization in past 3 months (GI bleed or
hemorrhagic stroke)
- unexplained HgB drop > 2 gm/dl in past 3 months
- chronic warfarin or anti-coagulation therapy (such as Lovenox)
- pregnant or nursing mothers
- allergic to fish, fish oil or fish products
- Participation in other trials of investigational products
- other characteristics as determined by the investigator that would make sudy
participation inappropriate
We found this trial at
1
site
University of Iowa With just over 30,000 students, the University of Iowa is one of...
Click here to add this to my saved trials
